Effective January 2, 2024, Harrow, Inc. appointed John P. Saharek as the President and Chief Executive Officer of the Company?s ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company. Mr. Saharek will continue to report to Mark L. Baum, Chief Executive Officer and Chairman of the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.61 USD | +37.61% | +55.12% | +51.52% |
02:00pm | Transcript : Harrow, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 13 | Harrow Health Q1 Core Net Loss Widens, Revenue Increases -- Shares Rise After-Hours | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.52% | 427M | |
+30.84% | 682B | |
+30.35% | 586B | |
-3.50% | 364B | |
+18.17% | 327B | |
+4.07% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.07% | 165B |
- Stock Market
- Equities
- HROW Stock
- News Harrow, Inc.
- Harrow, Inc. Appoints John P. Saharek as President and Chief Executive Officer of its ImprimisRx Division